Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
29 juin 2022 07h30 HE
|
Mindset Pharma Inc.
TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating...
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
22 juin 2022 07h30 HE
|
Mindset Pharma Inc.
TORONTO, June 22, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating...
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
10 juin 2022 08h00 HE
|
Mindset Pharma Inc.
TORONTO, June 10, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma to Participate in Upcoming Conferences in June 2022
07 juin 2022 07h45 HE
|
Mindset Pharma Inc.
TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
12 mai 2022 07h12 HE
|
Mindset Pharma Inc.
TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma to Participate in Upcoming Conferences in May 2022
04 mai 2022 07h30 HE
|
Mindset Pharma Inc.
TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds
19 avr. 2022 07h30 HE
|
Mindset Pharma Inc.
TORONTO, April 19, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma to Participate in Upcoming Conferences in April 2022
05 avr. 2022 07h30 HE
|
Mindset Pharma Inc.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
17 mars 2022 08h00 HE
|
Mindset Pharma Inc.
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma to Participate in Upcoming Investor Conferences in March 2022
03 mars 2022 07h00 HE
|
Mindset Pharma Inc.
TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...